NR 565 ADVANCED PHARMACOLOGY
FINAL EXAM STUDY GUIDE: 240
QUESTIONS WITH VERIFIED ANSWERS
& RATIONALES (2026 UPDATED) |
MOST RECENT | GRADED A+
Section 1: Pharmacokinetics & Pharmacodynamics
(Questions 1-10)
Q1: A patient with cirrhosis is prescribed lorazepam for anxiety. The nurse
practitioner selects this benzodiazepine over diazepam because lorazepam:
• A. Is metabolized by oxidation, which is faster in liver disease
• B. Undergoes glucuronidation, which is relatively preserved in hepatic
impairment ✓ [CORRECT]
• C. Is a prodrug requiring hepatic activation to become active
• D. Has a longer half-life and therefore requires less frequent dosing
Rationale: Lorazepam undergoes glucuronidation (Phase II metabolism), which is
relatively preserved in liver disease compared to oxidation (Phase I metabolism) used
by diazepam, making it safer in patients with hepatic impairment .
Q2: A patient taking warfarin achieves a stable INR of 2.5. After starting
amiodarone, the INR rises to 5.2. This interaction is best explained by which
mechanism?
• A. Amiodarone induces CYP2C9, increasing warfarin metabolism
• B. Amiodarone inhibits CYP2C9, decreasing S-warfarin metabolism ✓
[CORRECT]
• C. Amiodarone displaces warfarin from albumin binding sites
, • D. Amiodarone increases renal excretion of warfarin
Rationale: Amiodarone is a potent inhibitor of CYP2C9, the primary enzyme
responsible for metabolizing S-warfarin (the more potent isomer), leading to
decreased warfarin clearance and increased anticoagulant effect .
Q3: A drug has an ED50 of 10 mg and an LD50 of 100 mg. What is the
therapeutic index?
• A. 1
• B. 10 ✓ [CORRECT]
• C. 100
• D. 110
Rationale: The therapeutic index is calculated as LD50 divided by ED50 (100/10 =
10). A higher therapeutic index indicates a wider safety margin between effective and
toxic doses .
Q4: A patient with renal failure receives a loading dose of vancomycin but no
maintenance doses. The loading dose is based primarily on which
pharmacokinetic parameter?
• A. Volume of distribution, to achieve the target concentration
immediately ✓ [CORRECT]
• B. Clearance, to maintain the steady-state concentration
• C. Half-life, to determine the dosing interval
• D. Bioavailability, to compensate for first-pass metabolism
Rationale: The loading dose is calculated based on the volume of distribution and
the desired target plasma concentration to rapidly achieve therapeutic levels,
independent of clearance or half-life .
Q5: A patient taking phenytoin has subtherapeutic drug levels despite
adherence. The nurse practitioner discovers the patient takes antacids with each
dose. This interaction occurs through which mechanism?
, • A. Antacids increase phenytoin metabolism via CYP induction
• B. Antacids decrease phenytoin absorption by increasing gastric pH ✓
[CORRECT]
• C. Antacids displace phenytoin from plasma proteins
• D. Antacids increase phenytoin renal excretion
Rationale: Antacids increase gastric pH, which can reduce the dissolution and
absorption of weakly acidic drugs like phenytoin. Concurrent administration should
be separated by at least 2 hours .
Q6: A patient asks why the initial dose of digoxin is higher than subsequent
maintenance doses. The nurse practitioner explains that this is based on which
pharmacokinetic principle?
• A. Loading doses are used to achieve steady-state concentration
rapidly ✓ [CORRECT]
• B. Loading doses increase the therapeutic index of the drug
• C. Loading doses prevent first-pass metabolism
• D. Loading doses increase the volume of distribution
Rationale: A loading dose rapidly achieves the target steady-state plasma
concentration that would otherwise require approximately 4–5 half-lives to reach
with maintenance dosing alone .
Q7: Which factor most significantly increases the volume of distribution of
lipophilic drugs in elderly patients?
• A. Decreased total body water and increased body fat ✓ [CORRECT]
• B. Increased cardiac output and enhanced perfusion
• C. Decreased plasma protein binding and hypoalbuminemia
• D. Increased hepatic blood flow and enzyme activity
Rationale: Aging increases adipose tissue and decreases total body water, which
causes lipophilic drugs to distribute more extensively in fat tissue, increasing the
volume of distribution .
, Q8: Which drug requires monitoring for both therapeutic effect and toxicity
due to a narrow therapeutic index?
• A. Digoxin ✓ [CORRECT]
• B. Metformin
• C. Lisinopril
• D. Furosemide
Rationale: Digoxin has a narrow therapeutic index; subtherapeutic doses are
ineffective, and supratherapeutic levels can cause toxicity, including cardiac
arrhythmias. Monitoring levels and electrolytes is essential .
Q9: Why are sulfonylureas ineffective in patients with type 1 diabetes?
• A. They require functioning pancreatic beta cells ✓ [CORRECT]
• B. They decrease insulin secretion
• C. They work by increasing insulin sensitivity only
• D. They are only effective intravenously
Rationale: Sulfonylureas stimulate insulin release from beta cells. In type 1 diabetes,
beta-cell function is absent or significantly diminished, making these agents
ineffective .
Q10: Which statement indicates correct understanding of omeprazole therapy?
• A. "I should take this drug immediately after meals."
• B. "This drug decreases acid production in my stomach." ✓ [CORRECT]
• C. "I will need to monitor my blood sugar closely."
• D. "I should take an antacid at the same time."
Rationale: Omeprazole is a proton pump inhibitor that suppresses gastric acid
secretion. It is typically taken 30–60 minutes before meals. Antacids should be taken
at different times to avoid interactions .
Section 2: Endocrine Pharmacology (Questions 11-20)
FINAL EXAM STUDY GUIDE: 240
QUESTIONS WITH VERIFIED ANSWERS
& RATIONALES (2026 UPDATED) |
MOST RECENT | GRADED A+
Section 1: Pharmacokinetics & Pharmacodynamics
(Questions 1-10)
Q1: A patient with cirrhosis is prescribed lorazepam for anxiety. The nurse
practitioner selects this benzodiazepine over diazepam because lorazepam:
• A. Is metabolized by oxidation, which is faster in liver disease
• B. Undergoes glucuronidation, which is relatively preserved in hepatic
impairment ✓ [CORRECT]
• C. Is a prodrug requiring hepatic activation to become active
• D. Has a longer half-life and therefore requires less frequent dosing
Rationale: Lorazepam undergoes glucuronidation (Phase II metabolism), which is
relatively preserved in liver disease compared to oxidation (Phase I metabolism) used
by diazepam, making it safer in patients with hepatic impairment .
Q2: A patient taking warfarin achieves a stable INR of 2.5. After starting
amiodarone, the INR rises to 5.2. This interaction is best explained by which
mechanism?
• A. Amiodarone induces CYP2C9, increasing warfarin metabolism
• B. Amiodarone inhibits CYP2C9, decreasing S-warfarin metabolism ✓
[CORRECT]
• C. Amiodarone displaces warfarin from albumin binding sites
, • D. Amiodarone increases renal excretion of warfarin
Rationale: Amiodarone is a potent inhibitor of CYP2C9, the primary enzyme
responsible for metabolizing S-warfarin (the more potent isomer), leading to
decreased warfarin clearance and increased anticoagulant effect .
Q3: A drug has an ED50 of 10 mg and an LD50 of 100 mg. What is the
therapeutic index?
• A. 1
• B. 10 ✓ [CORRECT]
• C. 100
• D. 110
Rationale: The therapeutic index is calculated as LD50 divided by ED50 (100/10 =
10). A higher therapeutic index indicates a wider safety margin between effective and
toxic doses .
Q4: A patient with renal failure receives a loading dose of vancomycin but no
maintenance doses. The loading dose is based primarily on which
pharmacokinetic parameter?
• A. Volume of distribution, to achieve the target concentration
immediately ✓ [CORRECT]
• B. Clearance, to maintain the steady-state concentration
• C. Half-life, to determine the dosing interval
• D. Bioavailability, to compensate for first-pass metabolism
Rationale: The loading dose is calculated based on the volume of distribution and
the desired target plasma concentration to rapidly achieve therapeutic levels,
independent of clearance or half-life .
Q5: A patient taking phenytoin has subtherapeutic drug levels despite
adherence. The nurse practitioner discovers the patient takes antacids with each
dose. This interaction occurs through which mechanism?
, • A. Antacids increase phenytoin metabolism via CYP induction
• B. Antacids decrease phenytoin absorption by increasing gastric pH ✓
[CORRECT]
• C. Antacids displace phenytoin from plasma proteins
• D. Antacids increase phenytoin renal excretion
Rationale: Antacids increase gastric pH, which can reduce the dissolution and
absorption of weakly acidic drugs like phenytoin. Concurrent administration should
be separated by at least 2 hours .
Q6: A patient asks why the initial dose of digoxin is higher than subsequent
maintenance doses. The nurse practitioner explains that this is based on which
pharmacokinetic principle?
• A. Loading doses are used to achieve steady-state concentration
rapidly ✓ [CORRECT]
• B. Loading doses increase the therapeutic index of the drug
• C. Loading doses prevent first-pass metabolism
• D. Loading doses increase the volume of distribution
Rationale: A loading dose rapidly achieves the target steady-state plasma
concentration that would otherwise require approximately 4–5 half-lives to reach
with maintenance dosing alone .
Q7: Which factor most significantly increases the volume of distribution of
lipophilic drugs in elderly patients?
• A. Decreased total body water and increased body fat ✓ [CORRECT]
• B. Increased cardiac output and enhanced perfusion
• C. Decreased plasma protein binding and hypoalbuminemia
• D. Increased hepatic blood flow and enzyme activity
Rationale: Aging increases adipose tissue and decreases total body water, which
causes lipophilic drugs to distribute more extensively in fat tissue, increasing the
volume of distribution .
, Q8: Which drug requires monitoring for both therapeutic effect and toxicity
due to a narrow therapeutic index?
• A. Digoxin ✓ [CORRECT]
• B. Metformin
• C. Lisinopril
• D. Furosemide
Rationale: Digoxin has a narrow therapeutic index; subtherapeutic doses are
ineffective, and supratherapeutic levels can cause toxicity, including cardiac
arrhythmias. Monitoring levels and electrolytes is essential .
Q9: Why are sulfonylureas ineffective in patients with type 1 diabetes?
• A. They require functioning pancreatic beta cells ✓ [CORRECT]
• B. They decrease insulin secretion
• C. They work by increasing insulin sensitivity only
• D. They are only effective intravenously
Rationale: Sulfonylureas stimulate insulin release from beta cells. In type 1 diabetes,
beta-cell function is absent or significantly diminished, making these agents
ineffective .
Q10: Which statement indicates correct understanding of omeprazole therapy?
• A. "I should take this drug immediately after meals."
• B. "This drug decreases acid production in my stomach." ✓ [CORRECT]
• C. "I will need to monitor my blood sugar closely."
• D. "I should take an antacid at the same time."
Rationale: Omeprazole is a proton pump inhibitor that suppresses gastric acid
secretion. It is typically taken 30–60 minutes before meals. Antacids should be taken
at different times to avoid interactions .
Section 2: Endocrine Pharmacology (Questions 11-20)
